Skysis’ well-designed and executed market insights programs drive optimal decision-making throughout the commercialization process helping biopharma companies achieve a competitive advantage for their products and therapies.
Competitive intelligence is a key differentiator of our Market Insights practice. Our professionals combine advanced degrees with 20+ years’ experience in the biopharma industry and/or medical field. Teams are tailored to address client-specific needs, choosing from MDs with clinical research experience, PhDs with clinical and commercial industry experience, and PharmDs and MBAs with significant competitive intelligence experience.
Skysis Competitive Intelligence services include:
Key Opinion Leader Interviews
Lifecycle Management and Strategic Planning Initiatives
Full Functional Outsourcing
We measure value by our clients’ ability to integrate our competitive insights into their brand planning and corporate strategy development.
Experiencing an increase in marketing activities due to product launch, annual planning or acute competitive threats? Count on Skysis’ experienced professionals and proven processes to overcome limitations in resources and expertise when you need it most.
Learn more about Skysis’ comprehensive, detailed, and fully integrated commercialization planning framework. This customized deliverable includes cost roll-up across all initiatives, with a revenue forecast to generate financial scenarios (i.e. P&L, NPV, Cash Flow, etc.) from starting point to 5 years post launch.
From early development and pivotal clinical trials to launch and lifecycle management, Skysis MA professionals have the insight and expertise to navigate the changing healthcare landscape and understand the most influential levers that impact product access.
Is it time to start planning for loss of exclusivity or LOE? If your branded product faces patent expiry in the next 5 years or less, the timing is now for developing an LOE strategy. Let Skysis help you research options and design and implement a plan that minimizes generic erosion and capitalizes on specific generic opportunities.
Introducing “Two Thumbs Up,” a comprehensive offering from Skysis that enables biopharmaceutical professionals to confidently make the go/no-go decision relative to a drug’s commercial potential, regulatory pathway, and clinical development feasibility.
We measure value based on our ability to integrate competitive insights into a client’s brand planning and corporate strategy development. Skysis Competitive Intelligence professionals have earned advanced degrees and average twenty years’ experience in the pharmaceutical industry and/or medical field. Customize your team, choosing from MDs with clinical research experience, PhDs with clinical and commercial industry experience, and PharmDs & MBAs with significant competitive intelligence experience.